Recruiting for Clinical Trial: MPS-II (Hunter Syndrome) with Pabinafusp-Alfa

Apr 29, 2022 | Clinical Trials, News, Research

Mathias Schmidt, PhD, President and CEO of JCR Pharmaceuticals USA, discusses long-term efficacy and safety data of pabinafusp-alfa (Izcargo) in mucopolysaccharidosis type II (MPS II; Hunter syndrome). (Data from this study was recently presented at WORLDSymposium 2022.

Dr. Schmidt says, the phase 3 portion of the study is open for recruitment. Watch the short video >>